JMJoseph Mikhael

Joseph Mikhael

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph Mikhael has a total of 299 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study

    by Faith E. Davies, Beth Faiman, Hayley Beer, Anne Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J. Blake Bartlett, Yi Han, Georgia Attfield, et al.

    Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.

  • International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

    by Efstathios Kastritis, Shaji K. Kumar, Vincent S. Rajkumar, Wee Joo Chng, Luciano Costa, Monika Engelhardt, Wilson Gonsalves, Vania Hungria, Jens Hillengass, Dragan Jevremovic, et al.

    Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.

  • Open Access

    An Equity-Embedded, Protocol-Agnostic Pre-Trial Navigation Model for Canadian Blood Cancer Trials: Findings from the Myeloma Canada Phase 0 Workshop

    by Gabriele Colasurdo, Alvina Nadeem, Nina Mason, Juliette Royer, Stephanie Soltys, Henry Chan, Richard K. Plante, Julie Stakiw, Joseph R. Mikhael, Michelle Oana

    Background: Inequitable access to clinical trials persists in blood cancers despite ongoing equity, diversity, and inclusion (EDI) efforts. Despite the critical role of clinical trials in improving survival and outcomes, recruitment remains suboptimal, limiting patient access to potentially life-saving therapies. Practical and scalable approaches are therefore needed to address the non-medical barriers that hinder patient readiness upstream of enrolment. Methods: Myeloma Canada led a national, multi-phase initiative using human-centred design (HCD) to operationalize EDI in clinical trials. Following an initial systems level workshop, the two-day Phase 0 workshop used a HCD approach that convened a purposively selected multidisciplinary group of stakeholders to co-design operational solutions for non-medical barriers affecting trial participation for patients. Given the use of purposive sampling, the results should be interpreted as reflecting a balanced range of diverse, informed perspectives across the Canadian clinical trial ecosystem. Results: Participants identified persistent cultural, logistical, financial, and linguistic barriers, along with fragmented awareness of available supports. Across diverse personas and care settings, all groups independently converged on a human-centred, equity-focused pre-trial navigation model supported by simple digital tools, including AI-enabled infrastructure drawing on curated resources from validated sources with appropriate governance, privacy, and oversight. Digital tools were proposed to support, rather than replace, human support and to align with existing health system realities. Conclusions: This hypothesis-generating work proposes a feasible, sustainable, and scalable equity-embedded, protocol-agnostic navigation framework. Its external hub-and-spoke structure can reduce non-medical barriers, strengthen trial access and accrual, and enhance representativeness. Pilot implementation that assesses feasibility, uptake, workflow impact, equity effects, and implementation burden is warranted.

  • Open Access

    REVEAL-MM: Retrospective Evaluation of Variables in Early Assessment and Landmark trends in Multiple Myeloma – a US Claims-Based Case-Control Study

    by Faith Davies, Beth Faiman, Hayley Beer, Anne Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J. Blake Bartlett, Yi Han, Georgia Attfield, et al.

    Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9,466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.

  • Open Access

    Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

    by Ola Landgren, Noa Biran, Elizabeth K. O'DOnnell, Joseph Mikhael, Katja C. Weisel, Annemiek Broijl, Saad Z. Usmani, Philippe Moreau, Francesca M. Gay, Roberto Mina, et al.

    The treatment of newly diagnosed multiple myeloma (NDMM) has advanced rapidly in recent years, with the standard of care (SOC) now including not only triplet combinations of proteasome inhibitors (PIs), immunomodulatory agents, and steroids but also quadruplet combinations that add the anti‐CD38 monoclonal antibodies isatuximab (Isa) or daratumumab (D) to a triplet backbone. In addition to the widely used bortezomib–lenalidomide–dexamethasone (VRd) combination, an alternative triplet option that can be considered is the combination of the second‐generation PI carfilzomib (K) with lenalidomide–dexamethasone (KRd). In patients with transplant‐eligible NDMM, US treatment guidelines have included the KRd triplet as a recommended regimen and the quadruplet combinations of either Isa‐KRd or D‐KRd as additional options. However, currently, KRd does not have regulatory approval for use in the NDMM population. This review describes the current evidence for using KRd as a backbone of therapy in frontline treatment regimens for patients with NDMM. In addition to multiple studies that have examined the KRd triplet in this population, several clinical trials have been investigating anti‐CD38‐KRd quadruplets. The data reported from these various trials are revealing deep and durable responses with Isa‐KRd and D‐KRd, including minimal residual disease negativity. Importantly, these benefits have also been demonstrated in high‐risk NDMM populations. KRd‐based combinations may represent a suitable alternative to VRd for some patients. This article discusses measures that may help to establish KRd‐based quadruplets as an additional SOC in this setting, including proper patient selection, steps to mitigate safety concerns, and the establishment of optimal dosing schedules.


  • Top Cited Papers
    Open Access

    International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

    by Luciano J. Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Benjamin A. Derman, Maung M. Htut, Chandramouli Nagarajan, Cesar Rodriguez, Joshua Richter, et al.

    T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.


  • Down with dex!

    by Susan Harding, Joseph Mikhael


  • Open Access

    Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies

    by Paul G. Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D’aGostino, Pieter Sonneveld, Kamlesh Bisht, et al.

    The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone) and IKEMA (isatuximab–carfilzomib–dexamethasone vs. carfilzomib–dexamethasone) studies provide large datasets for retrospectively validating the prognostic value of the R2-ISS in relapsed/refractory multiple myeloma. Of 609 pooled patients, 68 (11.2%) were reclassified as R2-ISS stage I, 136 (22.3%) as R2-ISS stage II, 204 (33.5%) as R2-ISS stage III, 55 (9.0%) as stage IV, and 146 (24.0%) “Not classified”. Median progression-free survival was shorter among those reclassified as R2-ISS stage II (HR 1.52, 95% CI 0.979–2.358), stage III (HR 2.59, 95% CI 1.709–3.923), and stage IV (HR 3.51, 95% CI 2.124–5.784) versus stage I. Adding isatuximab led to longer progression-free survival versus doublet therapy (adjusted HR 0.544 [95% CI 0.436–0.680]), with a consistent treatment effect observed across all R2-ISS stages. This is the first study to validate the R2-ISS with novel agents, including anti-CD38 monoclonal antibodies, and to show that R2-ISS, as a prognostic scoring system, can be applied to patients with relapsed/refractory multiple myeloma.


  • Open Access

    Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma

    by Sophia S. Li, Robert Schuldt, Faiza Zafar, Tu My To, Archibong Yellow-Duke, Alina Levine, Allicia Girvan, Shelli Spence, Joseph Mikhael